Karen E Effinger1, Kayla L Stratton2, Paul Graham Fisher3, Kirsten K Ness4, Kevin R Krull5, Kevin C Oeffinger6, Gregory T Armstrong4, Leslie L Robison4, Melissa M Hudson7, Wendy M Leisenring2, Paul C Nathan8. 1. Department of Pediatrics, Emory University, 2015 Uppergate Dr., Rm 426I, Atlanta, GA 30322, United States; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, 2015 Uppergate Dr., Rm 426I, Atlanta, GA 30322, United States. Electronic address: karen.effinger@emory.edu. 2. Department of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, PO Box 19024, Seattle, Washington 98109, United States; Department of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, PO Box 19024, Seattle, Washington 98109, United States. 3. Department of Pediatrics, Stanford University, 750 Welch Road, Suite 317, Palo Alto, CA 94304, United States; Department of Neurology, Stanford University, 750 Welch Road, Suite 317, Palo Alto, CA 94304, United States; Department of Human Biology, Stanford University, 750 Welch Road, Suite 317, Palo Alto, CA 94304, United States. 4. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 735, Memphis, TN 38105, United States. 5. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 735, Memphis, TN 38105, United States; Department of Psychology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, United States. 6. Department of Medicine, Duke University School of Medicine, 2424 Erwin Dr., Suite 601, Durham, NC 27705, United States. 7. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 735, Memphis, TN 38105, United States; Department of Psychology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, United States; Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, United States. 8. Division of Haematology, Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada; Division of Oncology, Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada; Department of Paediatrics, University of Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada; Department of Health Policy, Management, and Evaluation, University of Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada.
Abstract
BACKGROUND: Although paediatric astrocytoma has an excellent 5-year survival rate, survivors remain at risk for morbidity and late mortality. This study aimed to estimate the risk of late mortality, chronic conditions, poor health status and social impairment in ageing paediatric astrocytoma survivors. METHODS: We longitudinally evaluated 1182 5-year astrocytoma survivors diagnosed between 1970 and 1986 and 4023 siblings enrolled in a retrospective cohort study. Kaplan-Meier estimates of late mortality and cumulative incidence of serious chronic conditions were estimated. Cox regression models provided hazard ratios (HRs) with 95% confidence intervals (CIs) for development of chronic conditions, and generalised linear models provided relative risks (RRs) of the poor health status and social outcomes. RESULTS: At 30 years from diagnosis, cumulative late mortality was 22.1% (CI 20.0-24.3%), primarily due to disease progression or recurrence. Compared with siblings, survivors were at increased risk of serious chronic conditions (HR 4.6, CI 3.8-5.5). Survivors reported higher rates of poor general health (RR 3.3, CI 2.8-3.8), poor mental health (RR 1.9, CI 1.7-2.1), functional impairment (RR 9.0, CI 7.7-10.5) and activity limitation (RR 3.6, CI 3.1-4.2) and lower rates of college graduation (RR 0.75, CI 0.69-0.82), marriage (RR 0.62, CI 0.58-0.66), employment (RR 0.75, CI 0.72-0.79) and household income ≥$40,000 (RR 0.68, CI 0.64-0.73). Even survivors without radiation exposure had elevated risk of chronic conditions, poor health status and social impairment compared with siblings. CONCLUSIONS: Survivors of paediatric astrocytoma are at high risk for long-term complications of their disease and its treatment. They require lifelong monitoring for late effects.
BACKGROUND: Although paediatric astrocytoma has an excellent 5-year survival rate, survivors remain at risk for morbidity and late mortality. This study aimed to estimate the risk of late mortality, chronic conditions, poor health status and social impairment in ageing paediatric astrocytoma survivors. METHODS: We longitudinally evaluated 1182 5-year astrocytoma survivors diagnosed between 1970 and 1986 and 4023 siblings enrolled in a retrospective cohort study. Kaplan-Meier estimates of late mortality and cumulative incidence of serious chronic conditions were estimated. Cox regression models provided hazard ratios (HRs) with 95% confidence intervals (CIs) for development of chronic conditions, and generalised linear models provided relative risks (RRs) of the poor health status and social outcomes. RESULTS: At 30 years from diagnosis, cumulative late mortality was 22.1% (CI 20.0-24.3%), primarily due to disease progression or recurrence. Compared with siblings, survivors were at increased risk of serious chronic conditions (HR 4.6, CI 3.8-5.5). Survivors reported higher rates of poor general health (RR 3.3, CI 2.8-3.8), poor mental health (RR 1.9, CI 1.7-2.1), functional impairment (RR 9.0, CI 7.7-10.5) and activity limitation (RR 3.6, CI 3.1-4.2) and lower rates of college graduation (RR 0.75, CI 0.69-0.82), marriage (RR 0.62, CI 0.58-0.66), employment (RR 0.75, CI 0.72-0.79) and household income ≥$40,000 (RR 0.68, CI 0.64-0.73). Even survivors without radiation exposure had elevated risk of chronic conditions, poor health status and social impairment compared with siblings. CONCLUSIONS: Survivors of paediatric astrocytoma are at high risk for long-term complications of their disease and its treatment. They require lifelong monitoring for late effects.
Authors: J Zabora; K BrintzenhofeSzoc; P Jacobsen; B Curbow; S Piantadosi; C Hooker; A Owens; L Derogatis Journal: Psychosomatics Date: 2001 May-Jun Impact factor: 2.386
Authors: Martin Benesch; Herwig Lackner; Petra Sovinz; Elisabeth Suppan; Wolfgang Schwinger; Hans-Georg Eder; Hans Jürgen Dornbusch; Andrea Moser; Karin Triebl-Roth; Christian Urban Journal: J Neurooncol Date: 2006-04-25 Impact factor: 4.130
Authors: Femke K Aarsen; Philippe F Paquier; Roel E Reddingius; Isabelle C Streng; Willem-Frans M Arts; Marjon Evera-Preesman; Coriene E Catsman-Berrevoets Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Paul G Fisher; Tarik Tihan; Patricia T Goldthwaite; Moody D Wharam; Benjamin S Carson; Jon D Weingart; Michael X Repka; Kenneth J Cohen; Peter C Burger Journal: Pediatr Blood Cancer Date: 2008-08 Impact factor: 3.167
Authors: D H Gutmann; S A Rasmussen; P Wolkenstein; M M MacCollin; A Guha; P D Inskip; K N North; M Poyhonen; P H Birch; J M Friedman Journal: Neurology Date: 2002-09-10 Impact factor: 9.910
Authors: Clare Frobisher; Emma R Lancashire; David L Winter; Helen C Jenkinson; Michael M Hawkins Journal: Int J Cancer Date: 2007-08-15 Impact factor: 7.396
Authors: Ian F Pollack; James M Boyett; Allan J Yates; Peter C Burger; Floyd H Gilles; Richard L Davis; Jonathan L Finlay Journal: Neuro Oncol Date: 2003-07 Impact factor: 12.300
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger Journal: JAMA Date: 2003-09-24 Impact factor: 157.335
Authors: Elochukwu F Ezenwankwo; Daniel A Nnate; Godspower D Usoro; Chimdimma P Onyeso; Ijeoma B Anieto; Sam C Ibeneme; Yumna Albertus; Victoria E Lambert; Antoninus O Ezeukwu; Ukachukwu O Abaraogu; Delva Shamley Journal: BMC Health Serv Res Date: 2022-02-21 Impact factor: 2.655
Authors: Katie A Devine; Salome Christen; Renée L Mulder; Morven C Brown; Lisa M Ingerski; Luzius Mader; Emma J Potter; Charlotte Sleurs; Adrienne S Viola; Susanna Waern; Louis S Constine; Melissa M Hudson; Leontien C M Kremer; Roderick Skinner; Gisela Michel; Jordan Gilleland Marchak; Fiona S M Schulte Journal: Cancer Date: 2022-04-18 Impact factor: 6.921
Authors: Nicole L Stout; Daniel Santa Mina; Kathleen D Lyons; Karen Robb; Julie K Silver Journal: CA Cancer J Clin Date: 2020-10-27 Impact factor: 508.702